Skip to main content

Amyloid β-Lowering Agent Fails in Phase III : Patients who received 800 mg of the drug saw the same cognitive decline as patients taking placebo.

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
Amyloid β-Lowering Agent Fails in Phase III : Patients who received 800 mg of the drug saw the same cognitive decline as patients taking placebo.

User login

Username

Password

Reset your password

Type	Lead	score